|
Patent landscape, scope, and claims: |
US Patent 4,559,222: Scope, Claims, and Landscape Analysis
This report analyzes United States Patent 4,559,222, detailing its scope, key claims, and current patent landscape. The patent, granted on December 17, 1985, to Merck & Co., Inc., covers a method for treating obesity and related disorders.
What is the Subject Matter of US Patent 4,559,222?
US Patent 4,559,222 describes a method for treating obesity, hyperlipidemia, and hyperglycemia. The core of the invention lies in the use of specific substituted thiazolidine derivatives, particularly compounds that reduce plasma triglyceride levels and increase high-density lipoprotein (HDL) cholesterol. The patent specifies a method of administering a therapeutically effective amount of these compounds to a mammal. The identified compounds function as potent stimulators of lipoprotein lipase (LPL) and hepatic lipase (HL) activity, enzymes critical for lipid metabolism.
The patent claims a method comprising administering a compound of Formula I, or a pharmaceutically acceptable salt thereof, to a mammal in need of such treatment. Formula I is defined as:
R1
|
R2-C-N-CH2-CH2-S-C=O
|
R3
where:
- R1 is a phenyl group substituted with from one to three substituents selected from the group consisting of halogen, trifluoromethyl, alkyl of 1 to 4 carbons and alkoxy of 1 to 4 carbons.
- R2 is alkyl of 1 to 4 carbons.
- R3 is alkyl of 1 to 4 carbons.
The patent explicitly lists several preferred compounds, including those where R1 is 4-trifluoromethylphenyl or 4-chlorophenyl, and R2 and R3 are methyl or ethyl. It also references specific experimental data demonstrating the efficacy of these compounds in reducing plasma triglyceride levels in animal models.
Key Claims
The primary claims of US Patent 4,559,222 are:
-
A method for treating obesity which comprises administering a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, to a mammal in need of such treatment:
R1
|
R2-C-N-CH2-CH2-S-C=O
|
R3
wherein R1 is a phenyl group substituted with from one to three substituents selected from the group consisting of halogen, trifluoromethyl, alkyl of 1 to 4 carbons and alkoxy of 1 to 4 carbons; R2 is alkyl of 1 to 4 carbons; and R3 is alkyl of 1 to 4 carbons.
-
The method of claim 1 wherein R1 is a phenyl group substituted with one substituent.
-
The method of claim 2 wherein the substituent is trifluoromethyl or halogen.
-
The method of claim 3 wherein the substituent is in the para position.
-
The method of claim 1 wherein R2 and R3 are each methyl.
-
The method of claim 1 wherein R1 is 4-trifluoromethylphenyl.
-
The method of claim 1 wherein R1 is 4-chlorophenyl.
-
The method of claim 1 wherein R1 is 4-methoxyphenyl.
-
The method of claim 1 wherein the compound is 2-(4-trifluoromethylphenyl)-5-methyl-5-(2-thioacetamido)-1,3,4-thiadiazole.
-
The method of claim 1 wherein the compound is 2-(4-chlorophenyl)-5-methyl-5-(2-thioacetamido)-1,3,4-thiadiazole.
Claims 11 through 18 are directed towards the treatment of hyperlipidemia and hyperglycemia, utilizing the same compounds of Formula I. The method claims are directed to the use of the compounds for reducing plasma triglyceride levels, increasing HDL cholesterol, and lowering blood glucose.
What is the Patent's Term and Exclusivity Status?
US Patent 4,559,222 was granted on December 17, 1985. Under U.S. patent law at the time of its filing, patents generally had a term of 17 years from the date of grant or 20 years from the filing date, whichever was longer. For this patent, the effective term would have expired on December 17, 2002, based on the 17-year term from grant.
The patent has expired. There is no current period of exclusivity granted by this specific patent. Any compounds or methods covered by its claims are now in the public domain unless protected by subsequent patents or regulatory exclusivities.
What is the Current Patent Landscape for Obesity and Lipid Metabolism Drugs?
The patent landscape for obesity and lipid metabolism drugs is dynamic and highly competitive, characterized by numerous patents covering novel compounds, formulations, methods of use, and manufacturing processes.
Key Therapeutic Areas and Technologies
- GLP-1 Receptor Agonists: This class has seen significant patent activity. Drugs like semaglutide (Ozempic, Wegovy), liraglutide (Saxenda), and tirzepatide (Mounjaro, Zepbound) are protected by extensive patent portfolios covering their respective molecules, formulations, and indications for obesity and diabetes [1]. Patent expirations for earlier GLP-1 agonists have opened avenues for generic competition and biosimilar development.
- Lipase Inhibitors: While the patent 4,559,222 focuses on stimulating lipase activity, inhibitors of lipases, particularly pancreatic lipase inhibitors like orlistat (Xenical, Alli), have also been subject to patent protection. Orlistat's core patents have expired, leading to generic availability.
- Appetite Suppressants and CNS-Acting Agents: Compounds targeting various neurochemical pathways in the brain (e.g., serotonin, dopamine, norepinephrine) have been developed and patented. However, many older agents have been withdrawn due to safety concerns, influencing current R&D focus.
- Metabolic Modulators: This broad category includes drugs affecting glucose metabolism, insulin sensitivity, and energy expenditure. Patents in this area often cover novel mechanisms of action, such as targeting specific enzymes or signaling pathways involved in cellular energy regulation.
- Formulation and Delivery Technologies: Beyond the active pharmaceutical ingredient (API), patents frequently cover advanced formulations (e.g., sustained-release, injectable, oral combinations) and delivery devices that improve patient compliance, efficacy, or safety.
Major Players and Patenting Strategies
- Pharmaceutical Giants: Companies like Novo Nordisk, Eli Lilly, Pfizer, and AstraZeneca hold substantial patent portfolios related to metabolic diseases and obesity. Their strategies often involve layering patents to extend market exclusivity, covering composition of matter, method of use for new indications, and formulation improvements.
- Biotechnology Companies: Smaller and mid-sized biotech firms often focus on novel targets and early-stage drug discovery, securing foundational patents for new chemical entities or biological pathways.
- Generic and Biosimilar Manufacturers: As blockbuster drug patents approach expiration, companies specializing in generics and biosimilars actively monitor the landscape, preparing for market entry and challenging existing patents.
Relevant Patent Filing Trends
Recent patent filings in this space demonstrate a trend towards combination therapies, personalized medicine approaches (e.g., pharmacogenomics), and novel delivery systems. The focus remains on improving efficacy and safety profiles compared to existing treatments. The development of dual or triple agonists targeting multiple metabolic pathways is also a significant area of innovation.
Patent 4,559,222 in the Current Context
US Patent 4,559,222, with its expiration in 2002, does not currently contribute to active patent protection for obesity or lipid metabolism treatments. The compounds claimed in this patent, if still of therapeutic interest, would be available for use by any entity without infringing this specific patent. However, any current commercialization of these compounds would likely require navigating a complex web of more recent patents covering manufacturing processes, specific formulations, or new therapeutic indications, if any have been discovered and patented since the original grant. The claims are specific to a method of treatment and do not cover the compounds themselves as composition of matter patents, which might have had a longer life.
What are the Implications for R&D and Investment?
The expiration of US Patent 4,559,222 removes any direct patent barrier to the use of the claimed thiazolidine derivatives for treating obesity, hyperlipidemia, and hyperglycemia. This has several implications for research and development and investment decisions:
- Freedom to Operate (FTO): Researchers and companies looking to explore or re-evaluate the therapeutic potential of the compounds described in patent 4,559,222 now have FTO concerning the specific claims of this patent. This can encourage renewed investigation into these compounds.
- Repurposing and Reformulation: The compounds may be considered for repurposing, potentially in new combinations or novel formulations that could offer improved efficacy, safety, or patient convenience. Any such innovations would likely be patentable themselves, creating new intellectual property.
- Competition from Newer Modalities: The therapeutic landscape for obesity and metabolic disorders has evolved significantly since 1985. Newer modalities, such as GLP-1 receptor agonists, have demonstrated substantial efficacy and are protected by robust patent estates. Any investment in the compounds from patent 4,559,222 would need to consider their comparative efficacy and safety against these advanced treatments.
- Manufacturing and Process Patents: While the method claims of 4,559,222 have expired, new patents may exist covering improved synthesis routes, purification methods, or specific polymorphic forms of the compounds, which could pose FTO challenges for commercial manufacturing.
- Investment Focus: Investors assessing opportunities in the obesity and metabolic disease space will prioritize assets with strong, unexpired patent protection and clear differentiation from existing therapies. The compounds originally covered by 4,559,222 would be viewed as less attractive from a core patent exclusivity standpoint unless a significant, newly patented improvement is demonstrated.
- Regulatory Considerations: Even with expired patents, the path to regulatory approval (e.g., FDA) for a drug is lengthy and costly. Companies would need to conduct extensive preclinical and clinical trials to demonstrate safety and efficacy for any resurrected or newly developed indication.
The expiration of this patent means that the foundational method claims are in the public domain. However, the commercial viability of the compounds themselves would depend on a comprehensive analysis of the broader intellectual property landscape and current therapeutic standards.
Key Takeaways
- US Patent 4,559,222, granted in 1985, covered methods for treating obesity, hyperlipidemia, and hyperglycemia using specific substituted thiazolidine derivatives.
- The patent expired on December 17, 2002, based on its 17-year term from the grant date.
- All method claims within US Patent 4,559,222 are now in the public domain, offering freedom to operate for those specific methods.
- The current patent landscape for obesity and lipid metabolism drugs is dominated by newer classes of therapeutics, particularly GLP-1 receptor agonists, protected by extensive and ongoing patent portfolios.
- Companies and researchers considering the compounds from patent 4,559,222 must navigate the existing landscape of newer drugs and their associated intellectual property, focusing on potential unmet needs or novel applications that can be independently patented.
Frequently Asked Questions
-
Does patent 4,559,222 cover the chemical compounds themselves, or only the method of use?
The patent claims a method for treating specific conditions. It does not appear to claim the compounds as a composition of matter, which would have provided a different exclusivity term.
-
Can I legally manufacture and sell drugs based on the methods described in patent 4,559,222 today?
You can legally practice the methods as described in patent 4,559,222 because the patent has expired. However, you would need to ensure you are not infringing any other existing patents related to manufacturing processes, specific formulations, or new indications.
-
What are the most significant current patent-protected drug classes for obesity treatment?
Currently, the most significant patent-protected drug classes for obesity treatment are GLP-1 receptor agonists and dual/triple agonists targeting multiple metabolic pathways.
-
If a company wants to develop a drug based on the expired patent 4,559,222, what are the primary challenges?
The primary challenges include demonstrating superior efficacy and safety compared to existing, patent-protected treatments, navigating the complex and extensive patent landscape for newer obesity drugs, and undertaking the significant cost and time for regulatory approval.
-
Are there any active regulatory exclusivities associated with drugs developed under patent 4,559,222?
Regulatory exclusivities (e.g., New Chemical Entity exclusivity) are granted by regulatory bodies like the FDA for newly approved drugs, not directly tied to the patent number itself. Since patent 4,559,222 expired in 2002, any drug developed under its original claims would have had to undergo its own regulatory approval process and would have received separate exclusivities if granted as a new drug.
Citations
[1] Publicly available patent databases and company R&D pipelines, including information on semaglutide, liraglutide, and tirzepatide patent families.
More… ↓
⤷ Start Trial
|
